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ABSTRACT: Consumption of CLA by lactating women affects
the composition of their milk, but the pattern of the different CLA
isomers is still unknown. We determined the effects of short ma-
ternal supplementation with CLA-rich Alpine butter on the occur-
rence of FA and CLA isomers in human milk. In an open random-
ized controlled study with a two-period cross-over design, milk
FA and CLA isomer concentrations were measured on postpar-
tum days ≥20 in two parallel groups of lactating women before,
during, and after consumption of defined quantities of Alpine but-
ter or margarine with comparable fat content (10 d of butter fol-
lowed by 10 d of margarine for one group, and vice versa in the
other). In the 16 women who completed the study (8/group),
Alpine butter supplementation increased the C16 and C18 FA, the
sum of saturated FA, the 18:1 trans FA, and the trans FA with CLA.
The CLA isomer 18:2 c9,t11 increased by 49.7%. Significant in-
creases were also found for the isomers t9,t11, t7,c9, t11,c13, and
t8,c10 18:2. The remaining nine of the total 14 detectable iso-
mers showed no changes, and concentrations were <5 mg/100 g
fat. A breastfeeding mother can therefore modulate the FA/CLA
supply of her child by consuming Alpine butter. Further studies
will show whether human milk containing this FA and CLA iso-
mer pattern acts as a functional food for newborns.
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Human milk (from German women) contains more long-
chain FA, with chain lengths of C20 to C24 including several
double bonds, than bovine milk fat. It contains a high propor-
tion of palmitic acid (16:0, 25.3%) and the isomeric groups
of 18:1 and 18:2, their main components being oleic acid (c9,
29.0%) and linoleic acid (c9,c12, 9.5%) (8).
The major CLA isomer is c9,t11-octadecadienoic acid (c9,t11
18:2) (1), also called rumenic acid (2). Although linoleic acid is
isom-erized by the enzymatic conversion of the c12 to the t11
bond by the anaerobe Butyrivibrio fibrisolvens in the rumen (3),
an estimated 64% of dairy milk fat CLA is of endogenous origin
(4). Total CLA and isomer concentrations in dairy milk fat de-
pend on feeding (i.e., pasture, oilseeds), the effects of altitude and
season, as well as the age and breed of the cow (5–7). Total CLA
and isomer concentrations in human milk depend on maternal
diet, stage of lactation, and de novo synthesis (8–12). As humans
do not synthesize PUFA, concentrations depend exclusively on
dietary fat intake (13). A study reporting CLA concentrations
(c9,t11 isomer) of 5.8 mg/g fat in milk from mothers on conven-
tional diets vs. 11.2 mg/g fat in Hare Krishna mothers hypothe-
sized that the difference was due to the large amounts of butter,
ghee, and cheese consumed by the latter (9). Chronic dietary
c9,t11 18:2 intake is thought to increase milk 18:2 c9,t11 concen-
trations (10). The proportions of partially hydrogenated oils and
ruminant fats in the diet also determine trans 18:1 isomeric distri-
bution (8), whereas maternal diet, i.e.. consumption of different
products or amounts of milk and meat, has been shown to corre-
late with differences in the CLA content of human milk (11).
Several effects of a high-CLA diet in animals and humans
have been described. However, for the effect of most interest
to us, that on neonatal development, only animal data are avail-
able: in rats, increased milk CLA concentrations in dams on a
high-CLA diet are associated with enhanced pup weight gain
(14). Recent studies have also shown that individual isomers
have different effects.
The aim of the present investigation as an essential prelimi-
nary to an efficacy study was to quantify CLA isomers and FA
concentrations in human milk from mothers consuming defined
quantities of CLA-rich Alpine butter.
SUBJECTS, MATERIALS, AND METHODS
Subjects. Following approval from the Institutional Review
Board of the Departments of Obstetrics and Urology at Zurich
University Hospital, healthy lactating women (n = 20) from the
Obstetrics Department were recruited on day (D) 2–4 postpar-
tum with their written informed consent. The noninclusion cri-
teria were pre-existing disease, medication other than vitamins
or minerals, HIV, mastitis, vegan or similar extreme diet, sub-
stance abuse (including alcohol), smoking, and inability to un-
derstand conversational German. Subjects started the study
from D20 postpartum when at home and healthy in lactation
stage III. 
Protocol. Dietary treatment was randomized in sealed opaque
envelopes according to an open controlled two-period cross-over
design in two parallel groups. Group 1 followed a normal diet at
home to day 20 postpartum (= study D1). From D1 through D10
(period 1), women were invited to supplement their diet with 40
g/d (4 packages of 10 g per 24 h) margarine (M) (Becel®;
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www.unilever.com) containing 24 g fat and 16 g water. From
D11 through D20 (period 2), the diet was supplemented with 30
g/d (3 packages of 10 g per 24 h) Alpine butter (AB) containing
25.7 g fat, 4.3 g water, and an average of 2.09 g CLA/100 g milk
fat (equivalent to approximately 0.5 g CLA/d). The difference
between the daily amount of M (30 g) and AB (40 g), respec-
tively, should result in an equal daily fat intake from the study
products. Group 2 women followed the same dietary schedule in
reverse order (period 1: AB; period 2: M). 
The Alpine butter originated from Alp Mutten (Graubün-
den, Switzerland, 2100 m altitude) and consisted of a blend of
five 2-kg portions that was produced between July 1 and 25,
2003, and stored at −20°C until use. The 10-g portions of this
blend contained 8.6 g fat, 1.4 g water, and 180.0 mg total CLA
(corresponding to 2.09 g total CLA/100 g milk fat). The pre-
dominant CLA isomers were c9,t11, t11,c13, t7,c9, and t8,c10
18:2. The FA and CLA composition of the two supplements is
shown in Table 1.
The women had to record the real daily intake of study prod-
ucts (weight). No additional Alpine milk or ruminant meat
products were allowed during the study. 
Dietary diary. The subjects documented potential additional
sources of CLA by recording every day the estimated intake
(volume or weight) of milk and dairy products (yogurt, sour
cream, cream, cheese, etc.) and meat (type). The amount of a
consumed product was given in the database of the EBIS pro-
gram (15), which transforms the consumed volume or weight
of a product in consumed grams fat by considering the prod-
uct’s specific percent fat. From the daily fat intake, the daily
CLA intake (milligrams) was calculated using the values of
Fritsche and Steinhart (16,17) for CLA amounts (grams CLA
per gram fat) in different foods (German and others); for
chicken or turkey the CLA values of Chin et al. (1) were used.
Milk sampling. On D1, D5, D10, D15, and D20, the subjects
took milk samples at home according to a standardized proce-
dure assisted by the principal investigator (IB): between 8:00
and 11:00 A.M. and 1–3 h after a continental breakfast, the
breast that was not actually used for infant feeding at the last
feed was emptied completely using an electric pump (Lacti-
naTM Electric plus; Medela AG, Baar, Switzerland) and the vol-
ume measured; 2 × 10-mL aliquots were transferred to plastic
tubes, cooled at +4°C (cold box), and stored at −20°C until
analysis. The remainder was fed to the baby.
Lipid extraction and analysis of FA. (i) Lipid extraction.
Milk fat was obtained gravimetrically using the Roese-Gottlieb
method, i.e., the fat globule membranes were disrupted with
ammonia and ethanol, the fat was extracted with diethyl ether
and petroleum ether, and the pure fat was stored at −20°C until
analysis (18). 
(ii) FA. The milk fat was dissolved in hexane, and the glyc-
erides were transesterified to the corresponding FAME using a
solution of potassium hydroxide in methanol (2 mol/L) as per
ISO standard 15885. FA composition was determined using a
gas chromatograph (GC; Agilent 6890, www.agilent.com)
equipped with an on-column injector and FID (19). Nearly 70
FA were separated on a capillary column (100 m × 0.25 mm ×
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TABLE 1 
Fatty Acids and CLA Isomers in Margarine and Alpine Butter
Supplementsa,b (per 100 g fat)a
FA Unit Margarine Alpine butter
14:0 g 0.83 6.99
15:0 g 0.02 1.29
16:0 g 10.83 19.88
17:0 g 0.04 0.78
18:0 g 3.75 11.25
18:1 c9 g 24.24 20.55
18:1 t6-8 g <0.01 0.16
18:1 t9 g <0.01 0.28
18:1 t12 g <0.01 0.18
18:1 t13-14 + c6-8 g 0.01 0.62
18:2 c9,c12 g 46.70 1.53
18:2 t7,c9 + t8,c10 + c9,t11 g <0.01 1.85
18:2 c9,c11 + t9,t11 + t11,c13 g <0.01 0.14
18:2 t12,t14 mg ND 20.4
18:2 t11,t13 mg ND 33.2
18:2 t10,t12 mg ND 2.8
18:2 t9,t11 mg ND 15.0
18:2 t8,t10 mg ND 1.7
18:2 t7,t9 mg ND 10.2
18:2 t6,t8 mg ND 4.7
18:2 c/t12,14 mg ND 5.3
18:2 t11,c13 mg ND 148.2
18:2 c11,t13 mg ND 3.4
18:2 t10,c12 mg ND 1.6
18:2 c9,t11 mg ND 1767.3
18:2 t8,c10 mg ND 29.5
18:2 t7,c9 mg ND 49.0
18:3 c9,c12,c15 g 0.12 1.24
Saturated FAc g 18.97 51.80
Monounsaturated FAd g 25.41 29.87
PUFAe g 47.72 6.72
18:1 transf g 0.03 5.94
Σ18:2 g 47.34 5.03
18:2 trans without trans CLAg g 0.08 1.45
18:2 trans with CLAh g 0.09 3.31
trans FA without CLAi g 0.11 7.72
trans FA with CLAj g 0.12 9.59
n-3k g 0.93 2.22
n-6l g 46.79 2.38  
aValues are means, n = 3. 
bA selected summation of FA that addresses specific points to the discussion
is presented. CLA isomers were analyzed by silver-ion HPLC and are ordered
according to their retention time; ND, not detectable; ttNMID, trans,trans
non-methylene interrupted diene; ccMID, cis,cis methylene interrupted
diene.
cAB: 4:0, 5:0, 6:0, 7:0, 8:0, 10:0, 12:0, 12:0 iso, 12:0 aiso, 13:0 iso, 14:0, 14:0
iso, 14:0 aiso, 15:0, 15:0 iso, 16:0, 16:0 iso, 16:0 aiso, 17:0, 17:0 iso, 17:0 aiso,
18:0, 19:0, 20:0, 22:0; M: 8:0, 10:0, 12:0, 14:0, 15:0, 16:0, 16:0 aiso, 17:0, 17:0
aiso, 18:0, 20:0, 22:0, 24:0.
dAB: 10:1, 14:1 ct, 16:1 ct, 17:1 ct, 18:1 -t4, -t5, -t6-8, -t9, -t10-11, -t12,
-(t13-14 + c6-8), 20:1 t, 20:1 c5, 20:1 c9, 20:1 c11; M: 16:1 c, 18:1
-t10, -c9, -c11, 20:1 c11.
eAB: 18:2 [Σ ttNMID, t9,t12, c9,t13 + (t8,c12), c9,t12 + (ccMID + t8,c13), t11,c15
+ t9,c12), -c9,c12, -c9,c15, 18:3 -c6,c9,c12, -c9,c12,c15, 18:2-(c9,t11 + -t8,c10
+ -t7,c9), -(t11,c13 + -c9,c11), -t9,t11, 20:2 cc n-6, 20:3n-6, 20:3n-3, 20:4n-6,
20:5n-3, 22:5n-3, 22:6n-3; M: 18:2 -(c9,t12 + ccMID + -t8,c13), -(t11,c15 +
t9,c12], -c9,c12, -c9,c15, 18:3 c9,c12,c15,  20:3n-3, 20:4n-6, 20:5n-3.
fAB: 18:1 t4 to t13-14; M: 18:1 -t10.
gAB: 18:2 trans [Σ ttNMID, t9,t12, c9,t13 + (t8,c12), c9,t12 + (ccMID +,t8c13,
t11,c15 + t9,c12]; M: 18:2 -(c9,t12 + t8,c13), -(t11,c15 + t9,c12).
hAB: 18:2 t + CLA trans (Σ C18:2 t7,c9, t8,c10, c9,t11, t9,t11, t11,c13); 
M: 18:2 -(c9,t12 + t8,c13), -(t11,c15 + t9,c12).
iAB: 14:1 t, 16:1 t, 17:1 t, 20:1 t, 18:1 trans and 18:2 trans (without CLA
trans); M: 18:1 t10, 18:2 -(c9,t12 + t8,c13), -(t11,c15 + t9,c12).
jAB: 14:1 t, 16:1 t, 17:1 t, 20:1 t, 18:1 trans, 18:2 trans and CLA trans; M:
18:1 t10, 18:2 -(c9,t12 + t8,c13), -(t11,c15 + t9,c12).
kAB: 18:2 -c9,c15 + -t11,c15, 18:3 c9,c12,c15, 20:3, 20:5, 22:5, 22:6; M:
18:2 -c9,c15, -t11,c15, 18:3 c9,c12c15, 20:3, 20:5.
lAB: 18:1 -t12, -c12, 18:2 –t9,t12, -c9,t12, -c9,c12, 18:3 c6,c9,c12, 20:2cc,
20:3, 20:4; M: 18:2 -c9,t12, -c9,c12, 20:3, 20:4.
0.20 µm, CP-Sil 88; www.varianinc.com) and quantified in ab-
solute values (g FA/100 g fat) using nonanoic acid as internal
standard.
(iii) CLA isomers. CLA isomers were analyzed by silver-ion
(Ag+) HPLC according to Rickert et al. (20), modified by Kraft
et al. (21). The analysis was performed on an Agilent LC series
1100 equipped with a photodiode array detector (234 nm) using
three ChromSpher Lipids columns in series (stainless steel, 250
× 4.6 mm, 5 µm particle size; Chrompack, Middleburg, The
Netherlands). The solvent consisted of UV-grade hexane with
0.1% acetonitrile and 0.5% ethyl ether (flow rate 1 mL min−1),
prepared fresh daily. Injection volumes were 10 µL, representing
<250 µg lipid. The identification of CLA isomers was based on
co-injection with commercial reference material and synthesized
CLA. The methyl esters of c9,t11 (98%), t10,c12 (98%), and
c9,t11 18:2 (75–78%) were obtained from Matreya Inc. (Pleas-
ant Gap, PA). Other CLA isomers were synthesized by isomeri-
zation of the commercially available reference (technical grade)
with I2 (22). The results were expressed as absolute values in mg
per 100 g fat. Fourteen different CLA isomers were separated by
this HPLC method (Fig. 1).
Statistical analysis. A power calculation was performed
based on an expected difference in CLA human milk content
of 30% between the two phases, Alpine butter (AB) and mar-
garine (M). The power was 80% for n = 8/group (α = 0.5).
Data were entered into Excel, analyzed in Systat for Win-
dows, version 10.2 (www.uic.edu/depts/accc/software), and ex-
pressed as means ± SD. The Kolmogorov–Smirnov test was
used for normality. Mean values were compared using the un-
paired two-tailed t-test for cross-over design and a P value of
<0.05. “Effect” refers to the differences between the two phases
AB vs. M of group-pooled data, and “period” to the period ef-
fect, i.e., the differences between the two phases AB and M of
group 1 vs. group 2.
RESULTS
Subjects. Three women withdrew because of lactation failure
and one developed diarrhea in response to Alpine butter, leav-
ing eight subjects per group. The groups did not differ statisti-
cally in age (27.8 ± 3.5 vs. 29.5 ± 5.6 yr, respectively), parity,
gravidity, gestational age at delivery, or body mass index (BMI)
during the study (Table 2).
Two group 2 women were excluded from the statistical
analysis of the CLA isomers because of technical problems in
the isomer analysis.
Study product intake and dietary diaries (Table 3). The
mean daily intake of margarine was 29.75 g (group 1) and
30.25 g (group 2) and that of Alpine butter 22.0 g (group 1) and
23.75 g (group 2). Study product intake was thus below the re-
quested level (margarine: up to 40.0 g; Alpine butter: up to 30.0
g). The higher intake of margarine than butter (P = 0.003) re-
sulted in an equal daily fat intake in both groups (P = 0.25 dif-
ferences between M and AB [effect] and differences between
the groups [period]). Fat intake was calculated from 60 g
fat/100 g (margarine) and 85.8 g fat/100 g (Alpine butter) as
specified in the Subjects, Materials, and Methods section. 
Dietary nonsupplement CLA intake, calculated from the
daily dietary records, also did not differ statistically (P = 0.52)
between phases or groups. Extremely small or zero amounts of
ruminant meat (beef) were recorded in both groups, as re-
quested (data not shown). 
Human milk. (i) Fat content. In neither group did fat con-
tent of human milk differ significantly between margarine and
butter phases (group 1: 3.3 ± 0.6 vs. 3.4 ± 1.6 g/100 mL milk;
group 2: 2.9 ± 1.3 vs. 3.4 ± 1.1 g/100 mL milk) corresponding
to a mean fat yield (g) per breast of 1.94 in the margarine and
1.90 in the butter phase (NS). 
(ii) FA. The sum of saturated FA increased by 2.057 g/100
g fat during the pooled butter phases (P = 0.03), 18:1 trans
FA by 0.428 g/100 g fat (P = 0.001), and trans FA with CLA
by 0.178 g/100 g fat (P = 0.005) (all without period effects).
There were significant pooled-group decreases in the butter
phases in the sum of PUFA (3.502 g/100 g fat), 18:2 (3.252
g/100 g fat), n-6 FA (3.571 g/100 g fat) (all P = 0.001), and
the sum of unsaturated FA (3.389 g/100 g fat; P = 0.02) (Table
4). The ratio of n-6/n-3 FA was lower in the butter than in the
margarine phases (mean: 13.7 vs. 17.9, P < 0.01), but the dif-
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FIG. 1. Silver-ion HPLC (Ag+-HPLC) separation of CLA methyl esters of
human milk using three columns in series (peak t6,t8 tentatively as-
signed according to Ref. 20).
TABLE 2
Population Demographic and Obstetric Dataa
Group 1 (n = 8) Group 2 (n = 8)
Mean SD Mean SD
Age (yr) 27.8 3.5 29.4 4.8
Parity (n) 1.6 0.5 1.8 0.7
Gravidity (n) 2.1 1.4 2.0 1.3
Gestational age (wk) at delivery 40.6 1.3 40.1 1.4
BMIb (kg/m2) 25.0 2.6 26.5 6.4
Days postpartum at study start 35.3 13.3 33.3 9.3
aValues between the groups do not differ. 
bMean of the five body weight values measured on the five sampling days.
BMI, body mass index.
ference was only minimal if we consider a ratio of 1 vs. 50 in
the corresponding study products (see Table 1).
The butter phases showed highly significant pooled-group
differences (g/100 g fat; all P < 0.001) vs. margarine in the fol-
lowing individual FA (Table 4): increases in C15 (0.116 g), C16
(1.507 g), C17 (0.072 g), C18 (0.960 g), and t9,c12 + t11,c15
18:2 (0.043 g); decreases in c9,c12 18:2 (3.632 g), c,c20:2n-6
(0.056 g), and 20:3n-6 (0.062 g) FA. 
CLA isomers. (i) At baseline. The overall baseline concen-
tration (D1, after normal nonstandardized diet, n = 14) showed
a predominance of the c9,t11 (277 ± 195 mg/100 g fat, range
77–800), t9,t11 (13 ± 7 mg/100 g fat, range 4–31), and t11,c13
(12 ± 10 mg/100 g fat, range 2–37) 18:2 isomers, and a total
CLA concentration of 352 ± 229 mg/100 g fat (range
103–956).
(ii) During the study. Analysis of the mean pooled study day
values (D5 + D10 and D15 + D20, respectively), showed sig-
nificant increases in t12,t14, t11,t13, t6,t8, c11,t13, t11,c13,
c9,t11, and t8,c10 18:2 as well as in the sum of CLA isomers
during Alpine butter intake of both groups (Table 4). There
were no significant period effects. Pooled-group increases of
the individual isomers, expressed per 100 g fat, are shown in
Figure 2. The sum of CLA isomers increased by 129.4 mg
(45.0%, P = 0.005) and the ratio of t11,c13 and t7,c9 18:2 iso-
mers by 70.8% (P < 0.0001). 
DISCUSSION
This study demonstrated that 10-d supplementation with
Alpine butter, a natural CLA-rich product, affects the FA and
CLA isomer content of human milk. 
Butter significantly increased the concentrations of saturated
FA. At study start (after a normal nonstandardized diet), 18
c9,t11 18:2 and total CLA concentrations in human milk were
277 ± 195 (range 7–800) and 352 ± 229 (range 103–956)
mg/100 g fat, respectively. The isomers showing the highest
increases in milk were t11,c13 (100.5%), t6,t8 (67.3 %), t12,t14
(61.3%), c9,t11 (49.7%), c11,t13 (39.6%), t11,t13 (34.0%), and
t8,c10 (28.2%) (all P < 0.05). 
Ethical limitations in standardization and compliance,
which was not 100% in our study (Table 3), make human data
inevitably more variable than their dairy counterparts. The
women were allowed to consume their total supplement per 24
h in as many portions as they wished, and we could not control
for the well-known differences in absorption relating to the
amount of fat per portion (23). However, our study has certain
advantages compared with others with human milk (9,10). The
cross-over design excluded interindividual differences and dif-
ferences due to lactation duration; all subjects consumed the
same supplements with defined fat content and FA composi-
tion; milk sampling was standardized (volume, time of day) to
minimize the effect of differential fat absorption (23) and milk
volume (24); dietary intake of other dairy and beef products
was recorded daily throughout the study; BMI was calculated
throughout; milk analysis was longitudinal, with two time
points per period. Since no significant differences were found
in compliance, BMI, dietary (nonsupplement) CLA intake, or
total milk fat content between periods or groups, these factors
can be excluded as accounting for the differential milk content
of FA or CLA isomers in response to butter supplementation. 
Our basal value in human milk for the predominant isomer
(c9,t11 18:2) (0.25 g/100 g fat) is similar to those reported by
Jensen et al. (0.19 and 0.18 g/100 g fat) (25,26), Park et al.
(0.21 g/100 g fat) (10), and Ritzenthaler et al. (0.28 g/100 g
total FA) (12) in lactating American mothers during the low-
dairy periods (10,25,26) or in baseline (12). However, McGuire
et al. (27) and Innis and King (28) recorded higher basal val-
ues (0.4 g/100 g fat) in American mothers, matching those in
German mothers (0.39 and 0.40 g/100 g fat) (29). 
The increase in the predominant c9,t11 isomer in our study
by 109.8 mg/100 g fat (49.7%) approximates that reported by
Park et al. (10) (64.6%) from the low to the high CLA dairy
period of their study and is higher than that reported by Ritzen-
thaler et al. (12) (29.0%) from baseline to 4 wk of consump-
tion of high-CLA cheese. Unlike us, earlier investigators into
human milk CLA content could identify, in addition to the pre-
dominant c9,t11 18:2 isomer, only t9,t11 (29), t10,c12
(12,27,29), t7,c9 (30), and t9,t11/t10,t12 18:2 (12). In milk
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TABLE 3
Documented Intake of Study Products (and corresponding fat and CLA) and Dietary CLA (pooled study days)
Group 1 (n = 8) Group 2 (n = 8)
M AB AB M Pa
Mean SD Mean SD Mean SD Mean SD Effectb Periodc
Study product intake
Amount (g/d) 29.75 10.91 22.00 7.67 23.75 6.81 30.25 8.05 0.003 NS
Fatd (g/d) 17.85 6.55 18.88 6.58 20.38 5.85 18.15 4.83 NS NS
CLAe (mg/d) <2 379.4 132.3 409.6 117.6 <2 <0.001 NS
Dietary intake
CLAf (mg/d) 81.1 79.7 64.9 52.3 109.7 104.2 70.9 63.4 NS NS
aUnpaired two-tailed t-test for cross-over design: NS, nonsignificant.
bEffect: overall (both groups) AB (Alpine Butter) vs. M (Margarine). 
cPeriod: AB vs. M of group 1 vs. group 2.
dCalculated from 85.8 g fat/100 g (AB) and 60 g fat/100 g (M). 
eC18:2 t7,c9 + t8,c10 + c9,t11 and C18:2 c9, c11 + t9,t11 + t11,c13. 
fC18:2 c9,c11 + t9,t11 + t11,c13 calculated by EBIS program (19) according to nutrition protocol.
from German women, c9,t11 18:2 accounted for no more than
0.39%, t9,t11 18:2 at most 0.04%, and t10,c12 18:2 at most
0.08% of total FA (29). For Yurawecz et al. (30), the t7,c9 18:2
isomer accounted for 5.5–9.9% of total CLA. In our study, the
c9,t11, t9,t11, t7,c9, and t10,c12 isomers accounted for 0.380,
0.019, 0.018, and 0.002% of total FA and for 79, 3.9, 3.6, and
0.3% of total CLA; these values are consistent with those indi-
cated above. 
The distribution of other FA in milk during the study peri-
ods reflects some but not all of the differences between supple-
ments (Table 1). The 18:1 trans FA other than trans10-11,
which occur in low concentrations in both study products, also
show low concentrations in human milk during both phases.
This aspect could be of interest because in recent years atten-
tion has been given to the potential impairment of EFA metab-
olism to their long-chain metabolites by the trans-isomers in
humans (31). It is therefore unlikely that the small amounts
found in human milk in our study have any important negative
effect on the newborn. The higher amounts of C15, C16, C17,
and C18 acids and the trans unsaturated octadecadienoic acids
(t9,c12 + t11,c15 18:2) are likely to have resulted from their
higher content in Alpine butter. C15 and C17 acids are synthe-
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TABLE 4
FA and CLA Isomers in Human Milk (per 100 g human milk fat) During Maternal Supplementation with Margarine and Alpine Butter
(pooled study days) 
Group 1 (n = 8) Group 2 (n = 8b)
M AB AB M Pc
FAa Unit Mean SD Mean SD Mean SD Mean SD Effectd Periode
14:0 g 5.13 0.73 5.66 1.06 5.99 1.38 5.67 1.18 NS NS
15:0 g 0.31 0.05 0.42 0.07 0.49 0.13 0.37 0.13 <0.001 NS
16:0 g 20.28 1.96 20.62 2.14 22.22 2.87 19.55 3.45 <0.001 <0.05
17:0 g 0.29 0.04 0.36 0.06 0.39 0.08 0.32 0.09 <0.001 NS
18:0 g 6.04 1.05 6.83 1.16 7.38 1.04 6.25 1.05 <0.001 NS
18:1 c9 g 26.38 3.19 26.16 3.75 26.91 3.54 27.02 3.50 NS NS
18:1 t9 g 0.30 0.11 0.28 0.14 0.27 0.07 0.27 0.12 NS NS
18:2 c9,c12 g 14.64 3.60 12.41 6.06 7.96 2.72 13.00 2.99 <0.001 NS
18:2 t12,t14 mg 1.46 0.62 2.90 1.56 2.77 1.90 2.06 0.92 0.007 NS
18:2 t11,t13 mg 4.18 1.57 6.83 2.24 6.43 4.07 5.72 1.90 0.03 NS
18:2 t10,t12 mg 2.49 0.99 3.71 1.63 2.40 0.78 3.17 0.34 NS NS
18:2 t9,t11 mg 14.8 12.9 19.4 14.8 13.4 11.8 14.6 11.7 NS NS
18:2 t8,t10 mg 3.21 0.61 3.21 1.27 2.96 1.50 2.88 0.72 NS NS
18:2 t7,t9 mg 4.01 1.25 4.35 1.16 4.40 1.35 4.45 0.92 NS NS
18:2 t6,t8 mg 0.46 0.16 0.90 0.34 0.83 0.23 0.58 0.22 0.002 NS
18:2 ct/tc12,14 mg 0.86 0.50 1.22 0.56 1.15 0.64 0.98 0.35 NS NS
18:2 t11,c13 mg 6.2 3.1 15.6 6.1 17.1 10.9 10.1 5.0 0.001 NS
18:2 c11,t13 mg 3.26 1.19 5.14 2.16 5.99 3.13 4.71 1.69 0.02 NS
18:2 t10,c12 mg 1.31 1.07 1.94 1.58 0.90 0.27 1.44 0.59 NS NS
18:2 c9,t11 mg 176.0 75.6 309.5 120.7 351.6 212.0 265.6 114.7 0.005 NS
18:2 t8,c10 mg 6.6 1.8 9.6 3.8 10.7 5.4 9.2 2.5 0.04 NS
18:2 t7,c9 mg 10.4 4.0 13.7 6.0 16.0 7.1 14.9 4.3 NS NS
ΣCLA mg 235.2 87.0 397.9 141.7 436.6 248.6 340.5 126.8 0.005 NS
18:3 c9,c12,c15 g 0.44 0.21 0.41 0.08 0.38 0.16 0.50 0.19 NS NS
20:3n-6 g 0.31 0.09 0.26 0.09 0.21 0.12 0.29 0.11 <0.001 NS
20:4n-6 g 0.32 0.12 0.29 0.12 0.19 0.09 0.26 0.06 <0.01 NS
Saturated FAf g 37.27 1.84 40.64 4.13 38.77 3.96 38.03 3.84 <0.05 NS
Monounsaturated FAg g 30.11 4.17 31.57 5.01 30.17 6.49 31.36 4.17 NS NS
PUFAh g 16.28 4.17 14.77 6.30 9.35 3.64 14.84 3.43 <0.001 <0.05
18:1 transi g 1.31 0.21 1.85 0.49 1.72 0.56 1.40 0.52 <0.001 NS
Σ18:2 g 14.69 3.69 13.30 6.10 8.19 3.20 13.30 3.14 <0.001 <0.05
trans FA with CLAj g 2.04 0.32 2.91 0.67 2.62 0.93 2.26 0.73 <0.001 NS
n-6k/n-3l 19.8 5.21 15.38 6.64 11.95 3.33 15.98 3.52 <0.01 NS
aCLA isomers and CLA were analyzed by silver-ion HPLC and are ordered according to their retention time.
bn = 6 for CLA isomers. 
cUnpaired two-tailed t-test for cross-over design: NS, nonsignificant.
dEffect: overall (both groups) AB (Alpine Butter) vs. M (Margarine). 
ePeriod: AB vs. M of group 1 vs. group 2.
.fFor footnote f see Table 1, footnote c.
gFor footnote g see Table 1, footnote d.
hFor footnote h see Table 1, footnote e.
iFor footnote i see Table 1, footnote f.
jFor footnote j see Table 1, footnote j.
kFor footnote k see Table 1, footnote l.
lFor footnote l see Table 1, footnote k.
sized by ruminant flora but not in humans owing to the uneven
number of carbon atoms (32). They thus act as markers of a
dairy fat diet (33,34). The highly significant decrease (3.63
g/100 g milk fat = 26.3%) in octadecadienoic acid (c9,c12
18:2) on butter vs. margarine is also probably due to its much
lower content in butter than in margarine (1.53 g vs. 46.70
g/100 g fat). The n-6 FA that occur at high concentrations in
margarine have an extremely low transfer into human milk. 
Mothers can rapidly and easy modulate the fat composition
of their milk by consuming Alpine butter (or related natural
dairy products). This could have positive implications for the
newborn. Several studies, most of them in animals, have indi-
cated the potential impact of CLA-rich milk on the develop-
ment of the newborn. One point could be the potential effect
on body weight. In rats, the c9,t11 18:2 isomer increases body
weight (14,35), whereas the t10,c12 18:2 isomer decreases it in
both mice (35,36) and humans [loss of body fat in diabetics
(37)]. Another point could be the protection of CLA-rich milk
against development of atopy. In rats and mice, oral supple-
mentation with 100 mg/kg CLA (isomer profile unknown) re-
duces allergic anaphylaxis (by decreasing blood pressure), va-
sodilatation, and scratching behavior in response to egg-white
lysozyme (38). However, further studies in humans are neces-
sary to confirm these effects and to show whether human milk
with a special pattern of FA and CLA could be a functional
food for newborns.
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